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TNF-α is the dominant cytokine in inflammatory osteolysis. Using mice whose BM stromal cells and osteo-
clast precursors are chimeric for the presence of TNF receptors, we found that both cell types mediated the 
cytokine’s osteoclastogenic properties. The greater contribution was made, however, by stromal cells that 
express the osteoclastogenic cytokine M-CSF. TNF-α stimulated M-CSF gene expression, in vivo, only in the 
presence of TNF-responsive stromal cells. M-CSF, in turn, induced the key osteoclastogenic cytokine recep-
tor, receptor activator of NF-κB (RANK), in osteoclast precursors. In keeping with the proproliferative and 
survival properties of M-CSF, TNF-α enhanced osteoclast precursor number only in the presence of stromal 
cells bearing TNF receptors. To determine the clinical relevance of these observations, we induced inflam-
matory arthritis in wild-type mice and treated them with a mAb directed against the M-CSF receptor, c-Fms. 
Anti–c-Fms mAb selectively and completely arrested the profound pathological osteoclastogenesis attending 
this condition, the significance of which is reflected by similar blunting of the in vivo bone resorption marker 
tartrate-resistant acid phosphatase 5b (TRACP 5b). Confirming that inhibition of the M-CSF signaling path-
way targets TNF-α, anti–c-Fms also completely arrested osteolysis in TNF-injected mice with nominal effect 
on macrophage number. M-CSF and its receptor, c-Fms, therefore present as candidate therapeutic targets in 
states of inflammatory bone erosion.
*OUSPEVDUJPO
Inflammatory osteolysis attends disorders such as rheumatoid 
and psoriatic arthritis, which are among the most crippling of 
skeletal diseases. In this circumstance, osteoclasts erode periar-
ticular bone, leading to joint collapse and disfigurement. The 
fact that large numbers of such osteoclasts appear juxtaposed 
to foci of synovitis suggests that the products of inflammation 
mediate cell recruitment.
Osteoclasts have the unique capacity to resorb bone and are derived 
from monocyte/macrophage precursors (1). The discovery that 
receptor activator of NF-κB ligand (RANKL) is the specific osteoclas-
togenic cytokine (2, 3) led to the development of techniques whereby 
pure populations of osteoclasts can be generated in culture and even-
tuated in targeted, antiresorptive therapeutic strategies (4).
Other cytokines, however, also have a significant impact on the 
osteoclastogenic process, not least of which is TNF-α. This mol-
ecule, which is produced in abundance in bone erosive diseases 
such as rheumatoid arthritis and periodontitis (5–9), profoundly 
accelerates the osteoclastogenic process (10). Interestingly, TNF-α 
alone is not sufficient to promote osteoclast precursor differentia-
tion but has an impact only on cells simultaneously stimulated, or 
primed, with RANKL (10). Thus, inflammatory osteolysis does not 
occur in RANK-deficient mice (11, 12).
The discovery that TNF-α is central to the bone loss attend-
ing inflammation led to the development of agents that specifi-
cally block the cytokine and thus arrest the resorptive process 
(13). Anti-TNF therapy is not without complication, however, as 
patients are prone to infections, likely reflecting immune sup-
pression. In addition, it appears that targeting of inflammatory 
cytokines such as TNF-α and IL-1 in combination is substantially 
more effective than suppression of only 1 (14). Thus, detailing 
the panoply of cytokines that mediate inflammatory osteolysis 
carries therapeutic implications.
Osteoclastogenesis requires participation of both osteoclast 
precursors, principally in the form of BM macrophages (BMMs), 
and BM stromal cells and their derivative osteoblasts. In general, 
pro-osteoclastogenic agents target BM stromal cells, which are 
the source of RANKL. RANKL, in turn, activates its receptor on 
BMMs, prompting them to assume the osteoclast phenotype. 
TNF-α exerts its osteoclastogenic effect by stimulating stromal 
cells to produce RANKL but, at high doses, also directly activates 
the osteoclast precursor (15).
Given that both osteoclast precursors and stromal cells are 
TNF-α targets, we determined their relative contributions to 
inflammatory osteoclastogenesis. We found that while the pres-
ence of the cytokine receptor on either cell type was sufficient 
to promote some degree of TNF-α–induced osteoclastogenesis, 
stromal cells made the greater contribution. Furthermore, TNF-α 
induces in vivo expression of the stromal cell product M-CSF, 
which maintains survival and longevity of osteoclast precur-
sors and organizes the cytoskeleton of the mature resorptive cell 
(16). The fact that M-CSF plays a central role in TNF-induced 
osteoclastogenesis is confirmed by the capacity of an antibody 
directed against the M-CSF receptor, c-Fms, to completely arrest 
pathological osteoclastogenesis and bone resorption, whether 
attending inflammatory arthritis or direct injection of TNF-α. 
M-CSF and its receptor, c-Fms, are therefore candidate therapeu-
tic targets for inflammatory osteolysis.
Nonstandard abbreviations used: BMM, bone marrow macrophage; IL-1Ra, IL-1 
receptor antagonist; MTT, 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazoliun  
bromide; RANK, receptor activator of NF-κB; RANKL, RANK ligand; TNFR, TNF 
receptor; TRACP 5b, tartrate-resistant acid phosphatase 5b; TRAP, tartrate-resistant 
acid phosphatase. 
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BM stromal cells and osteoclast precursors contribute to TNF-induced osteo-
clastogenesis in vivo. We have shown that both BM stromal cells and 
osteoclast precursors are direct targets of TNF-α in the osteoclas-
togenic process (10, 15). The goal of our first exercise was, there-
fore, to determine the relative contributions of each. To this end, 
we turned to chimeric mice in which either WT or p55/p75 TNF 
receptor–deficient (TNFR–/–) BM was transplanted into irradiated 
recipients bearing the same or reciprocal genotype. T cells were 
eliminated in vivo during the course of the experiment by injec-
tion of anti-CD4 and anti-CD8 mAbs (15). Thus, WT BM trans-
planted into irradiated TNFR–/– (WT to KO) mice serves as a model 
in which osteoclast precursors but not BM stromal cells express 
TNFRs whereas the opposite obtains in KO to WT chimeras. WT 
to WT and KO to KO irradiated and transplanted animals were 
used as positive and negative controls, respectively.
Validating the chimeric transplantation model, BMMs isolated 
from WT to KO mice expressed both TNFRs in quantities similar 
to their WT to WT counterparts (Supplemental Figure 1; avail-
able online with this article; doi:10.1172/JCI26132DS1). Simi-
larly, macrophages derived from KO to WT mice were identical 
in this regard to those of animals lacking receptors on both cell 
types (KO to KO).
Each group of chimeric mice was subjected to daily supracal-
varial administration of increasing doses of TNF-α. The animals 
were sacrificed on day 5, histological sections of the calvaria were 
stained for tartrate-resistant acid phosphatase (TRAP) activity, 
and osteoclast number was determined (Figure 1). As expected, KO 
to KO animals failed to respond to the cytokine while WT to WT 
animals generated osteoclasts in a dose-dependent manner. A sim-
ilarly progressive albeit more modest increase in osteoclast num-
ber occurred in mice in which TNFRs were absent in osteoclast 
precursors (KO to WT). The response to the cytokine was, how-
ever, substantially more blunted in chimeras lacking stromal cell 
TNFRs. Thus, while the presence of TNFRs on either stromal cells 
or osteoclast precursors was sufficient to promote some degree 
of osteoclastogenesis, optimal osteoclast recruitment required 
expression of the receptor by both cell types with the greater con-
tribution made by stromal cells.
TNF-α impacts the RANK/RANKL axis. Because the RANK/RANKL 
axis is central to osteoclast recruitment, we asked if it is differen-
tially impacted in the various chimeric mice (Figure 2A). Thus, 
we administered TNF-α or carrier for 5 days and assayed BM for 
both RANKL and its receptor. As we have shown, TNF-α induces 
RANKL gene expression in WT to WT but not in KO to KO mice 
(15). In keeping with their greater contribution to TNF-α–stimu-
lated osteoclastogenesis, TNFRs on stromal cells, but not preosteo-
clasts, were necessary for RANKL induction by the cytokine. On the 
other hand, RANK mRNA levels were equivalent whether osteoclast 
precursors, stromal cells, or both express TNFRs. Thus, whereas 
RANKL induction by TNF-α required direct targeting of stromal 
cells, RANK mRNA expression by BMMs may have been stimulated 
directly (WT to KO) or indirectly (KO to WT) by the cytokine.
M-CSF mediates TNF-induced osteoclastogenesis. To determine the 
mechanism by which TNF-α simulates RANK via a stromal cell–
dependent mechanism, we turned to another stromal cell–pro-
duced osteoclastogenic cytokine, namely M-CSF, and asked if the 
growth factor promotes RANK mRNA expression by BMMs. In 
fact, like TNF-α, M-CSF induced RANK gene expression in a dose-
dependent fashion (Figure 2B). Therefore, the indirect stimulatory 
effect of TNF-α on RANK mRNA expression may be mediated by 
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To further explore this issue, we asked if TNF-α induces 
M-CSF expression in vivo in a stromal cell–dependent fashion. We 
therefore injected TNF-α into the 4 chimeric species of mice for 
5 days, after which we assessed BM M-CSF mRNA levels. TNF-α 
induced M-CSF mRNA in WT to WT and KO to WT but not in 
WT to KO or KO to KO mice (Figure 2C). Hence, the capacity of 
TNF-α to stimulate M-CSF gene expression requires the presence 
of cytokine-responsive stromal cells.
M-CSF promotes osteoclastogenesis by stimulating proliferation 
and survival of osteoclast precursors (17). If M-CSF represents a 
means by which TNF-α indirectly promotes osteoclast recruitment, 
one would expect absence of TNFRs on stromal cells to dampen 
osteoclast precursor number. In this regard, TNF-α adminis-
tered to mice increased the percentage of BM cells expressing the 
macrophage marker CD11b (Figure 3). Furthermore, TNF-α– 
mediated enhancement of osteoclast precursor number required 
the cytokine receptor only on stromal cells, a source of M-CSF.
TNF-α enhancement of osteoclast precursor number is not mediated by 
IL-1. TNF-α–induced osteoclastogenesis reflects both IL-1–depen-
dent and –independent mechanisms (18). The IL-1 mediated event, 
while involving BMMs, also participates in the effect of TNF-α on 
stromal cells and has the capacity to directly induce RANKL expres-
sion (18). This observation raises the possibility that TNF-α–stimu-
lated M-CSF production, and thus enhancement of osteoclast pre-
cursor number, is mediated via IL-1. To address this issue, we used 
a VCAM-1 affinity column to isolate BM stromal cells from WT 
mice and those deleted of IL-1RI (18). The cells were then exposed 
to TNF-α or IL-1–α. As seen in Figure 4, TNF-α, but not IL-1–α, 
induced M-CSF gene expression in WT stromal cells, and the effect 
was not impacted by IL-1 receptor antagonist (IL-1Ra). The fact 
that IL-1 did not mediate TNF-α induction of M-CSF mRNA is 
further confirmed by the lack of impact of IL-1RI deletion. Again 
consistent with stimulated M-CSF synthesis, TNF-α enhancement 
of osteoclast precursor number in vivo was unaltered in mice lack-
ing IL-1–α or its receptor (Figure 5).
Stromal cells or BMMs mediate optimal inflammatory osteolysis. 
We have shown that the presence of TNFRs solely on osteoclast 
precursors is sufficient to optimize bone loss in inflammatory 
arthritis (15). On the other hand, stromal cells are the source of 
TNF-α–induced M-CSF, and we therefore asked if the same occurs 
only if they express TNFRs. Thus, arthrogenic serum or PBS was 
administered to the 4 species of chimeric mice (19, 20). By 7 days, 
all developed cutaneous inflammation (Figure 6A). Paw swelling 
was also present in each, which, while identical in the 3 species 
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mice (Figure 6B). Whereas periarticular inflammation was exten-
sive in the WT to WT, WT to KO, and KO to WT serum-injected 
mice, it was sparse in those devoid of TNFRs (Figure 6C). Impor-
tantly, inflammatory osteolysis, as manifested by the percentage 
of bone surface juxtaposed to osteoclasts, was indistinguishable 
in arthritic mice whether TNFRs were present on stromal cells, 
preosteoclasts, or both (Figure 6, D and E). In contrast, no sig-
nificant osteoclastogenesis obtained in serum-injected KO to KO 
mice or any species administered PBS. Finally, osteoclast precursor 
number, represented by CD11B expression, was also enhanced to 
similar degrees in the BM of the 3 TNFR-bearing chimeras (Figure 
7). These observations are in keeping with the hypothesis that, in 
the context of severe inflammation, TNF-α enhances osteoclast 
precursor number by stimulating stromal cell production of 
M-CSF (KO to WT) or acting in concert with constitutive levels of 
the latter cytokine (WT to KO).
Blockade of M-CSF–induced signaling prevents inflammatory osteolysis. 
The data presented thus far raise the possibility that M-CSF plays 
a central role in states of TNF-α–induced osteolysis, including 
inflammatory arthritis. To explore the clinical implications of this 
issue, we turned to a mAb generated against the M-CSF receptor, 
c-Fms (21). To determine its efficacy, we added increasing amounts 
of the antibody to cultures of WT BMMs in the presence of M-CSF 
alone or induced to undergo osteoclastogenesis by M-CSF and 
RANKL. After 3 days, we determined the number of BMMs and 
osteoclasts, respectively. Figure 8 shows that substantial osteoclast 
arrest occurred relative to control (0 ng/ml) at a dose (10 ng/ml) of 
the antibody at least 1 order of magnitude lower than that impact-
ing macrophage number (100 ng/ml).
This observation prompted us to assess the effect of the anti– 
c-Fms mAb in inflammatory arthritis. Thus, WT mice adminis-
tered arthrogenic serum received daily injections of anti–c-Fms 
mAb or PBS. Nonarthritic animals received only PBS. Seven days 
later, cutaneous inflammation (Figure 9A) and paw thickness (Fig-
ure 9B) of mice treated with the antibody or PBS were indistin-
guishable. Histological examination of the ankles confirmed the 
abundance of inflammation in each and its absence in nonarthrit-
ic animals (Figure 9C). As expected, those serum-treated animals 
receiving PBS underwent extensive osteoclastogenesis with bone 
resorptive cells juxtaposed to virtually the entire inflamed bone 
surface (Figure 9, C and D). On the other hand, antibody-treated 
mice exhibited a total arrest of arthritis-induced osteoclastogen-
esis despite persistence of profound inflammation.
In keeping with the clinical implications of these observations, 
the increase in bone resorptive activity induced by inflammatory 
arthritis was completely prevented in antibody-treated animals 
(Figure 9E). Despite a small but significant decrease in serum tar-
trate-resistant acid phosphatase 5b (TRACP 5b) levels in arthritic 
mice receiving anti–c-Fms as compared with naive animals, the 
antibody appeared to exert a substantially greater impact on 
inflammation-induced than physiological osteoclastogenesis, as 
TRAP-expressing cells within the tibial metaphysis appeared to be 
abundant in each circumstance (Figure 9F).
Although TNF-α is a dominant mediator, the osteoclasto-
genesis of inflammatory arthritis is the product of a number 
of cytokines. Therefore, as a final exercise, we asked if arrest of 
M-CSF signaling specifically affects TNF-α–stimulated bone 
resorption. WT mice were administered supracalvarial TNF-α 
daily, with or without anti–c-Fms mAb. Once again, control ani-
mals received only PBS. By 5 days, TNF-α alone induced a marked 
osteoclastogenic response, which was completely prevented by 
c-Fms mAb (Figure 10, A and B). Similar to animals with inflam-
matory arthritis, this arrest of TNF-α–induced osteoclastogenesis 
was paralleled by blunting of in vivo bone resorption manifested 
by TRACP 5b serum to a level even lower than that of controls 
(Figure 10C). Again reflecting the relative sensitivity of osteoclast 
recruitment as compared with precursor number to anti–c-Fms, 
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in TNF-α–treated mice (70.7% ± 0.6% vs. 90.2% ± 2.0% of isolated 
BM cells) (Figure 10D).
%JTDVTTJPO
Rheumatoid arthritis is a complicated condition, as a host of 
cytokines produced by a variety of cells contributes to its patho-
genesis. While RANKL and IL-1 are important participants in 
development of focal bone erosions, which eventuate in joint col-
lapse, TNF-α is the principal and rate-limiting 
culprit, as its blockade dampens both the inflam-
matory and osteoclastogenic components of the 
disease (13). On the other hand, blockade of 
TNF-α alone is insufficient to optimize arrest of 
inflammatory joint disease, as coordinate treat-
ment with IL-1Ra is more effective (14). Added 
to the potential complications attending TNF-α 
inhibition, these observations underscore the importance of iden-
tifying new therapeutic candidates in this disease, a goal which 
can be achieved only by gaining insight into the means by which 
TNF-α impacts its target cells.
Inflammatory osteoclastogenesis represents a complex rela-
tionship between macrophages and mesenchymal stromal cells, 
including those in BM and synovium. Each produce, and are tar-
gets of, inflammatory cytokines such as TNF-α, which enhances 
osteoclastogenesis by impacting both families of cells (15, 18). The 
cytokine stimulates stromal cells to synthesize RANKL and IL-1. 
TNF-α also directly prompts macrophages to differentiate into 
osteoclasts when exposed to constitutive levels of the key osteo-
clastogenic cytokine, i.e., RANKL (10). Thus, our first exercise 
was to determine the relative contributions of stromal cells and 
macrophages to TNF-α–induced osteoclastogenesis. Because this 
undertaking required isolating the contribution of each in vivo, 
we turned to mice chimeric for TNFRs in the BM and stromal 
compartment and found that, while both were required for opti-
mal TNF-α–induced osteoclastogenesis, stromal cells had the 
greater impact. This pronounced contribution of stromal cells 
to the osteoclastogenic process involved stimulated production 
of RANKL. Alternatively, TNF-α–induced RANK mRNA levels in 
osteoclast precursors were similar whether TNFRs were present 
on macrophages, stromal cells, or both. Thus, enhanced RANK 
expression does not account for the dominant role played by 
stromal cells in TNF-α-stimulated osteoclast recruitment.
RANKL and IL-1 are produced by stromal cells under the 
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rect mediators of inflammatory osteolysis prompted us to ask 
if their participation in this disorder reflects additional osteo-
clastogenic cytokines, such as M-CSF, which may also represent 
therapeutic targets. M-CSF mediates survival and proliferation 
of macrophage precursors and their differentiation into mature 
phagocytes (17). Given the ontogeny of the osteoclast, it is not 
surprising that the cytokine also plays an important role in the 
maturation and survival of this cell. M-CSF also impacts the 
mature osteoclast by promoting organization of its cyto-
skeleton (16). The op/op mouse in particular underscores 
the central role the cytokine plays in the osteoclastogenic 
process. This animal, which bears a point mutation in the 
Csf1 gene coding for M-CSF, is born osteopetrotic due to 
failure to generate osteoclasts and is rescued by the cytokine 
(22). The transmembrane tyrosine kinase, c-Fms, is the sole 
M-CSF receptor (23, 24), and deletion of its gene leads to the 
same phenotype as the op/op mouse (25).
While M-CSF is constitutively produced by a range of 
mesenchymal cells, its regulated secretion has pathological 
consequences in the context of the osteoclast. Thus, absence 
of estrogen, the cause of postmenopausal osteoporosis, is 
due to enhanced bone resorption caused at least in part by 
increased production of M-CSF by BM stromal cells (26). 
Similarly, the enhanced osteoclastogenesis attending dele-
tion of the β3 integrin gene is due to stimulated M-CSF 
expression (16). As regards inflammatory osteolysis, the 
cytokine is increased in the serum of patients with rheuma-
toid arthritis (27) and those with severe ankylosing spondy-
litis (28) as well as in synovial fluid around loose joint pros-
theses (29). Taken together, these observations suggest that 
stromal cell–produced M-CSF may be an important media-
tor of TNF-stimulated osteoclastogenesis. In fact, we find 
that TNF-α induced M-CSF gene expression in vivo and did 
so only in the presence of stromal cell–residing TNFRs. The 
capacity of TNF-α to increase osteoclast precursor numbers, 
in vivo, is in keeping with the proproliferative and prosur-
vival properties of abundant M-CSF.
IL-1, whose expression by BMMs and stromal cells is also 
enhanced by TNF-α, mediates approximately 50% of the 
osteoclastogenic capacity of TNF-α (18). IL-1, however, does 
not participate in TNF-induced M-CSF production. Specifi-
cally, arrest of IL-1 signaling by either IL-1Ra or deletion of 
the functional IL-1 receptor has no effect on the capacity of TNF-α 
to promote M-CSF production or to increase osteoclast precursor 
number in vitro and in vivo. Thus, M-CSF appears to be a mediator 
of that component of TNF-stimulated osteoclastogenesis occur-
ring in an IL-1–independent manner.
The development of models of inflammatory arthritis in the con-
text of TNFR chimeric mice enables us to attribute various compo-
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to specific cell types. We previously noted that osteoclastogenesis 
induced by relatively modest levels of TNF-α requires TNF-respon-
sive stromal cells (15). On the other hand, an abundance of the 
cytokine, as obtains in inflammatory osteolysis, is capable of induc-
ing maximal osteoclastogenesis by directly targeting only osteoclast 
precursors in the presence of constitutive levels of RANKL (10, 15). 
In this study, we show that the reciprocal is also true. Thus, mice 
bearing TNFRs on stromal cells, but not osteoclast precursors, opti-
mize inflammation-induced osteoclast recruitment. These observa-
tions indicate that in situations of abundant TNF expression, such 
as rheumatoid arthritis, the cytokine’s effect is maximized by tar-
geting either the osteoclast precursor or the stromal compartment. 
The fact that TNF-α enhances osteoclast precursor number in the 
presence of only constitutive levels of M-CSF suggests that, like its 
interaction with RANKL, the inflammatory cytokine synergizes 
with M-CSF to enhance osteoclast precursor number.
These data, taken in concert, indicate that M-CSF is yet another 
cytokine playing a central role in inflammatory osteolysis and 
might be a therapeutic target. M-CSF, however, accelerates forma-
tion of osteoclasts by increasing their precursor pool, the majority 
of which does not become bone resorptive polykaryons, but host 
defense mononuclear phagocytes. Thus, the coincident immuno-
suppressive effect of inhibiting macrophage proliferation and sur-
vival as a means of arresting inflammatory periarticular erosion 
is a potential limitation of M-CSF blockade. On the other hand, 
anti–c-Fms mAb prevents RANKL and M-CSF–induced osteoclast 
formation at a concentration at least 1 order of magnitude less 
than its capacity to decrease cell number in vitro. This observa-
tion raises the possibility that, in the context of inflammatory 
osteolysis, osteoclast recruitment is more sensitive to M-CSF inhi-
bition than is macrophage proliferation and/or survival. In fact, 
mice treated with carrier or anti–c-Fms mAb developed equiva-
lent periarticular inflammation while those receiving the anti-
body were completely free of pathological osteoclastogenesis and 
bone resorption. This observation reflects to a substantial degree 
arrest of TNF signaling, as similar results obtained in TNF-α– 
injected mice also receiving anti–c-Fms mAb. Like arthritic ani-
mals, those directly receiving TNF-α experienced complete arrest 
of osteoclastogenesis but only a modest decrease in macrophage 
number. Interestingly, nonpathological osteoclastogenesis located 
distant from the inflamed joint was robust in each case. While the 
enhanced sensitivity to c-Fms arrest of pathological, as compared 
with physiological, osteoclastogenesis remains unexplained, it 
may reflect participation of redundant cytokines. For example, the 
osteopetrosis and arrested osteoclastogenesis of the M-CSF–defi-
cient op/op mouse resolves with age due to expression of VEGF 
(30), GM-CSF, and/or IL-3 (31). While speculative, the possibility 
remains that these 2 cytokines substitute for M-CSF in a physi-
ological setting of osteoclast recruitment.
Thus, M-CSF joins the panoply of cytokines involved in the 
pathogenesis of inflammatory osteolysis. Although this study rep-
resents short-term arrest of M-CSF signaling initiated at induction 
of the arthritic process, the profundity of its effect on osteoclasts 
as compared with macrophages enhances its therapeutic appeal. 
The potential of M-CSF inhibition as a means of treating rheuma-
toid arthritis is underscored by the development of c-Fms–selec-
tive small molecules (32) and the capacity of the tyrosine kinase 
inhibitor drug Imatinib to target the receptor (33). Given the sig-
nificant complications encountered with other forms of anticyto-
kine therapy, however, the therapeutic targeting of M-CSF must be 
approached with caution (34).
.FUIPET
Mice. C57BL/6 mice deleted of genes coding for both TNFR type 1 and 
TNFR type 2 on a C57BL/6 background were generated as described (15). 
C57BL/6 WT mice were purchased from the Jackson Laboratory. Animals 
were housed in the animal care unit of the Department of Pathology, 
Washington University School of Medicine, and were maintained accord-
ing to the guidelines of the Association for Assessment of Laboratory Ani-
mal Care. All animal experimentation was approved by the Animal Studies 
Committee of Washington University School of Medicine.
Reagents. The following mAbs were obtained from BD Biosciences: purified 
rat anti-mouse VCAM-1 (no. 553330), purified rat anti-mouse CD3 molecu-
lar complex (no. 555273), FITC-conjugated rat anti-mouse CD11b (no. 
553310), purified hamster anti-mouse TNFR1 (no. 559915), PE-conjugated 
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Goat anti-rat IgG microbeads for immunopurification were obtained from 
Miltenyi Biotec. Recombinant murine TNF-α was prepared in our labora-
tory as described (15). Recombinant human M-CSF was generously provided 
by Daved H. Fremont (Washington University, St. Louis, Missouri, USA). 
Murine RANKL was expressed in our laboratory as described (10).
BM transplantation. Mice were killed by CO2 gas, and femoral BM cells 
were flushed with culture medium as described (35). VCAM-1 and CD3-
positive cells were depleted from BM by negative selection using MACS 
goat anti-rat IgG Microbeads (Miltenyi Biotec) as described (15). One day 
after administration of 10 Gy of total body γ-irradiation, we injected 1 × 106 
CD3 and VCAM-1 depleted BM cells in 100 μl PBS into 4- to 6-week-old 
male mice via tail vein.
In vivo T cell depletion. Female ICR-SCID mice (Taconic) were primed by 
intraperitoneal injection of 0.5 ml of incomplete Freund’s adjuvant. After 
7 days, the mice received intraperitoneal injections of 5 × 106 YTS cells, 
which secrete anti-CD4 antibodies, or H35 cells, which secrete anti-CD8 
antibodies (kindly provided by Osami Kanagawa, Washington University, 
St. Louis, Missouri, USA). One to 2 weeks later, ascites was recovered, incu-
bated at 37°C for 1 hour, and transferred to 4°C overnight. Cells and oil 
were removed by centrifugation, and ascites was stored at –80°C. Mice were 
administered 4 weekly injections of 50 μl of anti-CD4 and anti-CD8 ascites 
to assure arrest of T cell generation in vivo (15).
FACS analysis. To assess the number of osteoclast precursors, freshly isolated 
BM cells were incubated in NaN3 (0.1%) plus FBS-PBS (FBS, 1%) for 30 min-
utes with FITC-conjugated rat anti-mouse CD11b mAb. The samples were 
diluted with the same solution and analyzed by FACS for CD11b-express-
ing cells. To evaluate BM engraftment, BMMs were incubated for 30 minutes 
with anti-TNFR1 mAb and then for 30 minutes with FITC-conjugated anti-
IgG mAb. They were then washed and diluted with NaN3 plus FBS. A second 
aliquot of BM cells was incubated for 30 minutes with PE-labeled anti-TNFR2 
mAb. TNFR1 and TNFR2 expression were analyzed by FACS.
RNA preparation and RT-PCR analysis. Total RNA from BM cells was iso-
lated by RNeasy mini kit (QIAGEN). For RT-PCR analysis, cDNA was syn-
thesized from 1 μg of total RNA using reverse transcriptase and oligo-dT 
primers in a volume of 20 μl. PCR was performed with a cDNA reaction 
mixture using PCR supermix (Invitrogen Corp.) and appropriate primers in 
a volume of 50 μl. The following primers were used: GAPDH, 5′-ACTTTGT-
CAAGCTCATTTCC-3′ and 5′-TGCAGCGAACTTTATTGATG-3′; RANK, 
mouse RANK PCR Primer Pair (R&D Systems); RANKL, human/mouse 
TRANCE/TNFSF11 PCR Primer Pair (R&D Systems.); and M-CSF, 5′-
GACTTCATGCCAGATTGCC-3′ and 5′-GGTGGCTTTAGGGTACAGG-3′. 
Samples were transferred to a programmable thermal cycler (Hybaid; Ther-
mo Electron Corporation) preheated to 94°C. Each cycle consisted of a 
denaturation step at 94°C for 45 seconds, an annealing step at 55°C for 45 
seconds, and an extension step at 72°C for 45 seconds for RANKL, RANK, 
and GAPDH and a denaturation step at 94°C for 1 minute, an annealing 
step at 58°C for 1 minute, and an extension step at 72°C for 1 minute for 
M-CSF. We separated 10-μl aliquots of PCR products by electrophoresis 
on a 2.0% agarose gel.
Serum transfer arthritis. KRN-TCR transgenic mice on a C57BL/6 back-
ground were kindly provided by D. Mathis and C. Benoist (Harvard Uni-
versity Medical School, Boston, Massachusetts, USA). K/BxN mice, which 
spontaneously develop severe inflammatory arthritis (18) and whose serum 
immunoglobulin is arthrogenic in a T cell–independent manner (15), in 
mouse strains other than KRN, were generated by breeding KRN-TCR with 
nonobese diabetic mice (Taconic). Serum was obtained from 6- to 12-week-
old K/BxN mice, pooled, and stored in aliquots at –70°C. T cell–depleted 
WT to WT, WT to KO, KO to WT, and KO to KO mice were injected once 
intraperitoneally with 200 μl of serum or PBS. Paw thickness was measured 
with a caliper daily for 10 days. A second group of animals was sacrificed 
at day 7 for histology and FACS analysis. Paws were stripped of soft tissue, 
and bones and joints were subjected to histological examination and evalu-
ation of numbers of CD11b-positive cells.
Administration of anti–c-Fms antibody. AFS98, a rat monoclonal, anti-
murine c-Fms antibody (IgG2a) that inhibits M-CSF–dependent colony 
formation and cell growth by blocking the binding of M-CSF to its recep-
tor, has been described (21). The AFS98 hybridoma was kindly supplied 
by Shin-Ichi Nishikawa (Graduate School of Medicine, Kyoto University 
Medical School, Kyoto, Japan). The clone was maintained in HyQ-CCM1 
medium (HyClone), and the antibody was purified using Protein G (Sigma-
Aldrich). We administered intraperitoneally 500 μm of AFS98 in 500 μl of 
PBS or PBS alone every day for 7 days to arthritic or TNF-injected mice.
Macrophage proliferation assay. BMMs from WT mice were cultured with 
several doses of AFS98 mAb in the presence of 100 ng/ml M-CSF. After 
3 days, the number of viable cells was measured using the MTT (3-[4,5-
dimethylthiazol-2yl]-2,5-diphenyltetrazoliun bromide; Sigma-Aldrich) 
assay. In brief, 10 μl MTT (5 mg/ml) was added to 100 μl culture medium 
in each well and incubated at 37°C for 4 hours. We added 150 μl 0.04N 
HCl in isopropanol to each well to stop the reaction, and MTT absorbance 
was determined at OD of 570 nm.
Serum TRACP 5b assay. Serum was obtained 7 days after injection of 
arthrogenic serum or following 5 days of daily TNF-α administration. 
TRACP 5b levels were determined according to the protocol of the 
MouseTRAP Assay kit (IDS).
Histological analysis. Osteoclast number was determined using the Osteo-
measure System version 2.2 (Osteometrics Corp.).
Statistics. All data are expressed as mean ± SD. Statistical significance was 
calculated by 2-tailed Student’s t test.
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